Role of calcitonin gene-related peptide and brain natriuretic peptide to modulate the excitability state of trigeminal neurons: relevance to migraine pathology and treatment by Nistri, Andrea et al.
© 2015 Vilotti et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Journal of Receptor, Ligand and Channel Research 2015:8 31–41
Journal of Receptor, Ligand and Channel Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
31
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JRLCR.S50993
Role of calcitonin gene-related peptide  
and brain natriuretic peptide to modulate  
the excitability state of trigeminal neurons:  
relevance to migraine pathology and treatment
Sandra vilotti1
elsa Fabbretti2
Andrea Nistri1
1Neuroscience Department, 
international School for Advanced 
Studies (SiSSA), Trieste, italy; 
2Center for Biomedical Sciences 
and engineering, University of Nova 
Gorica, Nova Gorica, Slovenia
Correspondence: Andrea Nistri 
Neuroscience Department, international 
School for Advanced Studies (SiSSA),  
via Bonomea 265, 34136 Trieste, italy 
Tel +39 040 378 7718 
Fax +39 040 378 7702 
email nistri@sissa.it
Abstract: Hyperactivity of trigeminal sensory neurons is a major process to generate recurrent 
headache, typical of migraine attacks. How physiological nociception is converted into strong 
pathological pain remains, however, poorly understood. In recent years, certain neuropeptides 
and their receptors have been shown to modulate sensory neuron nociception and to contribute 
to the persistent hyperalgesia due to the sensory stimulus sensitization that defines the clinical 
experience of chronic pain syndromes, including migraine. Using calcitonin gene-related peptide 
(CGRP) and brain natriuretic peptide (BNP) as examples, this review addresses the mechanisms 
through which neuropeptides might modulate nociceptor activity. One attractive notion is that 
pain signaling by trigeminal sensory neurons is potently regulated by the ambient levels of these 
peptides: CGRP is thought to facilitate neuronal firing responsible for trigeminal sensitiza-
tion necessary to trigger headache, whereas BNP is proposed to act as a negative regulator of 
trigeminal neuron activity. For either peptide, the key target appears to be the ATP-gated P2X3 
receptor that, widely expressed by trigeminal sensory neurons, generates fast, large excitation 
to release glutamate onto second-order brain neurons. The fine balance between the activities of 
these peptides is suggested to ultimately determine whether nociception is perceived at higher 
center as a physiological or pathological response. Hence, the clinical goal of CGRP antagonism 
using either pharmacological receptor blockers or monoclonal antibodies (to sequester this 
peptide or to directly inhibit its receptor) is currently considered a novel approach for migraine 
prophylaxis and to treat acute headache attacks.
Keywords: trigeminal ganglion, headache, sensory neurons, P2X3, TRPV1
Introduction – migraine pain can arise via chronic 
dysfunction of nociceptive neurons
While the molecular mechanisms of nociceptive neuron signaling have been widely 
investigated,1 the pathophysiological basis of chronic pain is less understood. A proto-
typical case is the recurrent chronic headache of migraine, which is a highly prevalent 
and disabling neurovascular disorder2 affecting a significant proportion of the adult 
population worldwide, and representing an enormous socioeconomic and health care 
burden for both the individual and society.3–5
Migraine is characterized by attacks of headache associated with autonomic nervous 
system dysfunction, and in about one-third of the cases, with transient neurological 
symptoms termed “aura”, whereby aberrant visual perceptions are the commonest 
complaint.6 Despite the fact that the migraine attack etiology remains largely unknown, 
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evidence points to the notion that migraine headache results 
from strong activation of primary afferent neurons (trigeminal 
ganglion [TG] nociceptors) that innervate craniofacial tissues 
(including meninges and their blood vessels) and project to 
the trigeminal nucleus of the brainstem and spinal cord with 
further signal processing at higher brain centers.7–9 In physi-
ological conditions, membrane depolarization (arising from 
mechanical, thermal, or chemical stimuli) of the peripheral 
terminals of TG nociceptors widely distributed over the cran-
iofacial territory will, if sufficiently large to reach a certain 
threshold, evoke action potentials that propagate to the central 
nervous system. To decode such stimuli and convert them into 
sensory information, TG neurons express a range of recep-
tors/ion channels that confer stimulus-related excitation. The 
depolarization induced by sensory stimuli is then modulated 
by membrane ion channels (e.g. K+ channels) that constrain 
the excitation propagating via voltage-gated Na+ channels 
responsible for the generation of action potentials. Con-
veying painful signals to the brain, therefore, demands a 
delicate balance between excitatory and inhibitory processes 
at the level of TG neurons. When such a fine equilibrium is 
pathologically disrupted, sensitization develops, whereby TG 
neurons become hyperresponsive even to mild stimuli: in the 
case of migraine, this is an important phenomenon to trigger 
headache.10 Furthermore, allodynia, namely pain generation 
by non-noxious stimuli, can occur in response to peripheral 
and central inputs.10–12 Symptoms of sensitization during 
migraine include throbbing headache and its aggravation 
during routine physical activities that increase intracranial 
pressure such as coughing and bending over.13,14
The question then arises as to whether sensitiza-
tion can originate from functional changes in the recep-
tor proteins transducing the sensory stimulus and/or in 
the voltage-dependent ion channels controlling neuron 
excitability. Recent studies have demonstrated that trigeminal 
sensory neurons express a large number of integral membrane 
proteins that sense strong external stimuli like pungent odors, 
chemicals, or temperature changes. The interest in their role 
related to migraine resides in the possibility that such proteins 
can be important triggers of migraine pain attacks either via 
direct activation of trigeminal neuron firing or via release of 
local mediators, in turn, exciting trigeminal neurons. This 
complex scenario presumably requires a delicate equilibrium 
between mechanisms dampening or enhancing neuronal 
excitability, and its derangement may lead to acute and/or 
chronic headache.15 Due to space constraints, the present 
short review focuses on the mechanisms of trigeminal pain 
transduction and how two endogenous neuropeptides, namely 
calcitonin gene-related peptide (CGRP) and brain natriuretic 
peptide (BNP), may up- or downregulate it. These (and other) 
neuropeptides might also be the intermediaries of the action 
of certain external stimuli on trigeminal sensory neurons as 
outlined earlier. Updated reviews are currently available for 
general involvement of CGRP in pain processing,16,17 while 
the role of BNP in maladaptive sensory signaling is a more 
recent finding.18,19
Molecular mechanisms of 
nociceptors involved in migraine 
pain signaling: shifting targets can 
facilitate pain onset
A large body of evidence has identified membrane pro-
teins expressed on dural afferent nerve endings and on the 
soma of TG neurons and suggested to play an important 
role in migraine pathophysiology.20 Immunolabeling and 
retrograde-labeling experiments in rodents have revealed 
that most small- and medium-sized TG neurons innervating 
the dura express voltage-insensitive acid-sensing cationic 
channels (ASICs) as well as transient receptor potential 
(TRP) channels and purinergic P2X receptors.21–23 Although 
pharmacological block of cortical-spreading depression (the 
underlying process mediating aura) and TG activation was 
experimentally elicited by the potassium-sparing diuretic 
amiloride via an action proposed to suppress ASIC activity,23 
there is little evidence that prior to (or during) a migraine 
attack, the local extracellular pH values can fall to a level 
sufficient for strong ASIC activation.
TRP receptor/channels comprise a wide family of mem-
brane proteins with multifarious functions of relevance to 
pain processing.15,24 For instance, the potential role of TRPA1 
receptors in migraine has been considered because TRPA1 
agonists may trigger migraine headache in susceptible 
individuals.25–28 Nevertheless, TRPA1 receptors, which are 
expressed only by a small minority of sensory neurons,29 
are typically stimulated by reactive oxygen species, and it 
is currently unclear whether such agents are generated in 
sufficient amount to trigger migraine or are by-products of 
subsequent neurovascular dysfunction associated with head-
ache and contributing to sustain it. Recent results indicate that 
chemical irritants found as environmental pollutants may also 
stimulate TRPA1 channels and evoke headache.30
Among the family of TRP receptors that can contribute to 
triggering migraine attacks, transient receptor potential vanil-
loid (TRPV)-4 is expressed by meningeal fibers: its activation 
by cold temperature31 or airborne irritants32 produces afferent 
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nociceptive signaling from the head that may contribute to 
migraine headache. TRPM8 channels that are activated by 
cold are also proposed to be involved in triggering trigemi-
nal neuron activity33 in accordance with the notion that a 
TRPM8 gene variant confers susceptibility to migraine.34 
While several studies have demonstrated capsaicin (and 
heat)-sensitive TRPV1 channels to be important for the 
development of inflammatory, thermal pain conditions,35–37 
their ultimate role in migraine remains unclear, and there are 
no current antimigraine drugs blocking TRPV1 receptors in 
clinical use.
Cannabinoids have been commonly associated with 
analgesic effects. In the case of headache, trigeminal neurons 
express the G-protein-coupled CB1 receptors that are the 
principal transducers of the neuronal action of endogenous 
endocannabinoids like anandamine and 2-acylglycerol.15 The 
hypothesis of the role of endocannabinoids in migraine was 
proposed as part of a syndrome (clinical endocannabinoid 
deficiency) with facilitated onset of pain.38 This concept was 
supported by the clinical observation of low endocannabinoid 
levels in the cerebrospinal fluid of migraine patients.39 The 
role of endocannabinoids in trigeminal pain processing is 
complex because anandamide can produce contrasting effects 
on the trigeminovascular unit activity, in which neurons, glia, 
and local vascular elements interact at meningeal level.40,41 
Furthermore, anandamide exerts several cellular effects 
distinct from CB1 receptor activation, including activation 
of TRPV1 receptors.42 These multifarious actions by endo-
cannabinoids may ultimately converge onto the modulatory 
effects of neuropeptides.
A number of studies have proposed that an acute attack 
of migraine is associated with a large release of ATP into 
the extracellular compartment to stimulate nociceptors.43 
While ATP receptors constitute a heterogeneous population, 
those with ionotropic properties and therefore, producing rapid 
ion current responses, belong to the P2X subclass. Among 
ATP-sensitive P2X receptors, the P2X3 receptors are selec-
tively and almost exclusively expressed by sensory ganglion 
neurons,44,45 suggesting their key role in processing pain. The 
subject of P2X3 receptors has been reviewed in detail.46,47 
In the mouse TG, P2X3 receptors are expressed by the vast 
majority of sensory neurons that may also express receptors for 
capsaicin (TRPV1)48 and have been implicated in craniofacial 
pain,49,50 including migraine.47 These data highlight the role of 
P2X3 receptors in nociception, and suggest that they may be 
an important target for novel analgesic drugs.51 For instance, 
dihydroergotamine (DHE), a nonselective ergot alkaloid 
derivative extensively used for the acute treatment of migraine, 
depresses ATP-mediated sensitization of TG neurons via 
downregulation of P2X3 receptors:52 these data suggest that 
the effectiveness of DHE in treating migraine might be partly 
due to its inhibitory effect on P2X3 receptors.
Ca2+-activated potassium channels may also contribute 
to controlling the hyperactivity of the trigeminocervical 
complex. Activation of neuronal large-conductance calcium-
activated potassium channels (BK
Ca
 or MaxiK) induces 
hyperpolarization of neurons,53 while intravenous administra-
tion of the MaxiK opener NS1619 dose-dependently inhibits 
neurogenic dural vasodilation in a model of trigeminovascu-
lar nociception.54 Among the group of voltage-independent 
K+ channels, the TRESK K2P channel modulates cellular 
excitability55 and is expressed in the TG. Although muta-
tion in the KCNK18 gene that encodes a protein member of 
the TRESK subfamily of leak K+ channels was reported to 
be linked to familial migraine,56 it was later suggested that 
KCNK18 might act as a modifier instead of being sufficient 
to cause typical migraine.57
Certain genetic mutations associated with familial 
migraine and affecting channels directly involved in hyperex-
citability have provided further information to understand the 
primary mechanisms underlying migraine pathophysiology. 
In particular, the genes known to cause familial hemiple-
gic migraine (FHM) are all involved in ion homeostasis 
across the neuronal cell membrane. Missense mutations in 
CACNA1A gene encoding the pore-forming subunits of the 
neuronal voltage-gated P/Q-type Ca2+ channel (Cav2.1) are 
reported to be the commonest cause of FHM type 1.58 Such 
mutation determines a major gain of function of Cav2.1 chan-
nels whose activation threshold is shifted to more negative 
membrane potential.59 Thus, not only this mutation favors 
neuronal excitability, but it also facilitates presynaptic release 
of transmitter, in particular glutamate.60
Migraine pain: sensitization process 
and its triggers
A number of studies and a large body of clinical as well as 
preclinical data have provided evidence for the involvement 
of sterile inflammation as one important mechanism for the 
activation of the migraine pain pathway.61 This process is 
purported to produce abnormal cross talk between neurons 
and nonneuronal cells in the TG and to reinforce activation 
and recruitment of immune cells releasing inflammatory 
agents to perpetuate sensitization.62–65 A recent study with in 
vitro TG cultures and a cell-line of macrophages has, in fact, 
shown how co-culturing these cells enhances phagocytic 
activity of macrophages and augments functional responses 
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by P2X3 receptors.64 During neurogenic inflammation, 
several neuropeptides, neuromodulators, and other signaling 
molecules are released from neurons and glial and inflamma-
tory cells of the trigeminovascular system. Pro-inflammatory 
cytokine levels have been found to be elevated in the plasma 
and in the cerebrospinal fluid of migraineurs.66–68 Bradykinin, 
histamine, serotonin (5-HT), and prostaglandin E2 cause 
mechanical sensitization and increase the excitability of 
somatic69 and meningeal nociceptors.10,11 Other inflammatory 
mediators like interleukins 1 (IL-1), 6 (IL-6), and 8 (IL-8) 
and tumor necrosis factor α exert their effects through the 
endogenous release of eicosanoids and sympathetic amines.70,71 
Increased nitric oxide (NO) production within the meninges 
may also contribute to migraine headache in patients.72 These 
inflammatory mediators collectively modulate the activity of 
various ion channels.73,74
Neuropeptides as modulators of 
nociceptors in migraine
The seminal observation that a pharmacological antagonist 
of the endogenous neuropeptide CGRP was a potent anti-
migraine drug75 catalyzed a strong focus on the action of 
CGRP in migraine. CGRP is a 37-amino acid neuropeptide 
derived from the gene encoding calcitonin by alternative 
splicing of mRNA and proteolytic processing of its precur-
sor.76,77 CGRP exists as two isoforms, α- and β-CGRP.78,79 
α-CGRP is predominant in the central and peripheral 
nervous systems, while β-CGRP is mainly present in the 
enteric nervous system.80 Jugular plasma concentrations of 
CGRP are increased during attacks of migraine.81 In addition, 
release of CGRP is produced by electrical stimulation of TG 
fibers.82 Chemical stimuli that activate, for example, TRPA1 
or TRPV1 receptors, or endogenous mediators liberated by 
neuroinflammatory cells increase the release of CGRP.82–84 
These data have, therefore, led to consider CGRP as a major 
“migraine mediator” as recently reviewed.16,17,85,86
CGRP is known to mediate neurogenic inflammation in 
peripheral tissues by increasing blood flow, and by recruiting 
immune cells, that may, in turn, activate sensory neurons.87 
In accordance with this notion, the peptide evokes strong 
stimulation of NO synthesis and release from trigeminal 
ganglia88 as well as liberation of inflammatory cytokines.89 
Furthermore, CGRP can promote the release of endogenous 
algogenic mediators like bradykinin from TG satellite cells,63 
thus contributing to the creation of a chemical milieu that 
facilitates sensory neuron activity. Its receptors are expressed 
in most peripheral components of the trigeminovascular sys-
tem, including blood vessels, Schwann cells, dural mast cells, 
satellite glial cells, and a subpopulation of TG neurons.90 
The importance of CGRP in the pathophysiology of migraine 
pain is supported by the fact that its intravenous administra-
tion causes delayed migraine-like headache in migraineurs, 
whereas CGRP receptor antagonists are proving effective 
in treating migraine,91 in line with the notion that migraine 
patients may somehow be hypersensitive to the CGRP-
positive modulation of nociception.75,92 It has been suggested 
that CGRP may mediate cross talk between TG neurons and 
satellite glial cells63 resulting in the increased expression 
and/or membrane targeting of specific pain receptors, such 
as ATP-gated P2X3, as well as an increased production of 
other inflammatory mediators, like IL-1β, thus sensitizing 
nociceptors and reinforcing neuroinflammation.93,94
An interesting issue concerns the origin of endogenous 
CGRP release with particular relevance to the migraine 
attack. Recent studies have suggested that low levels of endo-
cannabinoids may decrease their inhibitory control over the 
trigeminovascular system in migraine patients, a phenomenon 
that, in turn, may lead to increased CGRP.95 The action of 
endocannabinoids can also include a site in the brainstem to 
regulate trigeminal excitability.96 The mechanism of action 
of endocannabinoids in migraine remains, however, incom-
pletely understood in view of the activation of TRPV1 recep-
tors by anandamide and the implications of this result for the 
control of the local vasculature at meningeal level.
Gain of function of P2X3 receptors 
is an important mechanism of 
CGRP action
CGRP has been demonstrated to upregulate the membrane 
expression and function of P2X3 receptors86,94,97 through 
enhancing gene transcription and receptor membrane 
targeting.98 The mechanisms of P2X3 facilitation mediated 
by CGRP involve the activation of complex intracellular 
pathways and depend on protein kinase A (PKA) and pro-
tein kinase C (PKC) activity.94,98 It is noteworthy that only 
a minority of TG neurons can bind CGRP94 suggesting that 
the action of this peptide is discrete and can perhaps be 
amplified via further signaling processes within and between 
TG cells. In vivo studies confirm that CGRP injection into 
the temporomandibular joint capsule leads to early, PKA-
dependent increase in P2X3 receptors of the spinal trigeminal 
nucleus neurons.97
The potentiating action by CGRP on P2X3 recep-
tors is typically slow as it requires approximately 1 hour 
to develop fully, and it persists long after the peptide is 
eliminated.94 Importantly, this effect of CGRP is selective 
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for P2X3 receptors because, in TG cultures, it does not 
affect TRPV1 receptors.94 Furthermore, it has been proposed 
that neuronal P2X3 receptor activation and ensuing depolar-
ization can also release CGRP, thereby perpetuating a self-
supporting process for TG neuron sensitization.20
A significant component of the action by CGRP occurs 
indirectly, through the release of the algogenic neurotrophin 
brain-derived neurotrophic factor (BDNF).98 In accor-
dance with this view, P2X3 receptor expression is pro-
moted by CGRP/BDNF-dependent activation of calcium/
calmodulin-dependent kinase II and of the transcription 
factor CREB.98 Patients show significantly higher BDNF 
serum levels during migraine attacks.68,99 BDNF is a key 
mediator of plasticity in trigeminal nociceptive pathways,100 
and it has been shown to facilitate P2X3 receptor function.98 
Thus, CGRP and BDNF may be viewed as a combinatorial 
stimulus to facilitate TG sensitization.
The constitutive upregulation of P2X3 receptors in TG 
of the mouse model of FHM-1 is due to the higher level of 
CGRP release probably caused by increased Ca2+ inflow via 
gain of function of Cav2.1 channels.63,101,102 Furthermore, 
the perturbed intracellular Ca2+ homeostasis of such neurons 
enhances calcineurin activity with consequent change in the 
delicate intracellular balance between phosphorylation and 
dephosphorylation processes of P2X3 receptors with a posi-
tive impact on their function.101 Thus, preclinical and clinical 
data concur to show a pivotal role of CGRP in the migraine 
pain attack and suggest upregulated P2X3 receptors as a 
major contributor to TG sensitization.
Clinical pharmacology of CGRP 
antagonists to treat headache
The growing evidence linking migraine to neuropeptide 
signaling emphasizes the view that neuropeptide receptors 
represent an important area for pharmacological treatment. 
Despite recent advances in the structure of CGRP receptors 
obtained with crystallography, the design of effective CGRP 
antagonist remains a significant challenge in view of the het-
eromeric nature of the receptor complex.103 Table 1 summa-
rizes a few recent data for CGRP inhibitors based on receptor 
antagonists (the “gepants”) or monoclonal antibodies used 
for current clinical investigations. Detailed reviews on this 
subject are also available.17,91,103
 CGRP antagonists appear to be attractive new drugs 
because they lack vasoconstrictor effects that limit the use of 
other migraine therapies by patients with cerebral or coronary 
vascular disease.114–116 It is noteworthy that, since antago-
nists can possess distinct species specificity for the CGRP 
receptor,103 the present discussion is primarily centered on 
human studies. In a Phase II double-blind randomized clinical 
trial of 126 patients with migraine, the olcegepant response 
rate to block a migraine attack was comparable to that of 
triptans.75 Its tolerability was good, but this drug could only 
be administered by intravenous injection,75 thus represent-
ing a pitfall for treatment accessibility and repetition. More 
recently developed CGRP antagonists are available as oral 
formulation. Some of them (namely telcagepant/MK-0974 
and MK-3207) were shown to be effective against migraine, 
but, due to liver toxicity concerns, their development was 
discontinued.117,118 Three new CGRP receptor antagonists 
(BI 44370 TA, BMS-927711, and MK-1602) have com-
pleted Phase II trials, although only two have been reported 
(BI 44370 TA and BMS-927711) (Table 1).
A recent positron emission tomography study in man 
has shown that telcagepant achieved only low receptor 
occupancy at an efficacious dose, suggesting that large-
scale antagonism of brain CGRP receptors is unlikely to be 
required for migraine efficacy.119 It is, however, feasible that 
central CGRP receptor antagonism may provide additional 
therapeutic benefits.119
Table 1 Current CGRP antagonists/antibodies in clinical trial for migraine therapy
Code name Type Indication Administration route Clinical phase References
BiBN4096BS  
(olcegepant)
CGRP receptor antagonist Acute treatment intravenous Phase ii 75,104–106
Bi 44370 TA CGRP receptor antagonist Acute treatment Oral Phase ii 107
BMS-927711 CGRP receptor antagonist Acute treatment Oral Phase ii 108,109
MK-1602 CGRP receptor antagonist Acute treatment Oral Phase ii in progress 
(NCT01613248)
LY2951742 Humanized antibody against CGRP Prophylactic treatment Subcutaneous Phase ii 110,111
ALD403 Humanized antibody against CGRP Prophylactic treatment intravenous Phase ii 112
LBR-101 Humanized antibody against CGRP Prophylactic treatment Subcutaneous Phase ii 113
AMG 334 Humanized antibody against CGRP 
receptor
Prophylactic treatment Subcutaneous Phase ii in progress 
(NCT01952574)
Abbreviation: CGRP, calcitonin gene-related peptide.
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An alternative approach to pharmacological antagonists 
is the use of antibodies to target CGRP or its receptor. 
The sustained inhibition of CGRP signaling produced by 
monoclonal antibodies pharmacokinetically differentiates 
them from the CGRP antagonists, and renders the use of 
antibodies more suitable as prophylactic treatment rather 
than acute migraine medication.
One advantage with the antibody therapies is that they 
are structurally very different from the CGRP antagonists; 
thus, it is less likely that similar liver toxicity problems will 
be encountered. However, they are of high cost, and at least, 
some of them require an injectable route of administration. 
Moreover, the potential onset of immunological reactions 
should be borne in mind, and chronic depletion of CGRP 
may have adverse side effects actually induced by the 
lack of this peptide. While monoclonal antibodies are not 
expected to cross the blood–brain barrier in physiological 
conditions, the integrity of this barrier during an attack of 
migraine with associated release of circulating inflammatory 
factors remains a subject for future studies. Hence, it is not 
clear whether these antibodies exert their pharmacological 
effects simply through a peripheral site of action. There are, 
in fact, suggestions that CGRP antagonists may work partly 
through a central mode of action,120 even if this hypothesis 
is not without controversies121,122 and not fully consistent 
with recent functional imaging data.119 It should, however, 
be recalled that the TG is outside the blood–brain barrier 
even in physiological conditions, and it remains an acces-
sible target for these antibodies (or, indeed, pharmacological 
blockers). Thus, it will be of great interest to examine if the 
CGRP antibodies display comparable long-term efficacy as 
the CGRP antagonists.
There are no clinical data based on multicenter trials, in 
which the efficacy of antibodies against the CGRP receptor 
(or the peptide itself) has been compared versus administra-
tion of CGRP pharmacological antagonists. Furthermore, it 
is not known if there is any advantage in terms of migraine 
control in using an antibody therapy directed against 
the CGRP receptor rather than the circulating peptides. 
These issues will also need extensive future studies in view 
of the possible long-term changes in CGRP receptor func-
tion, once the natural ligand activity has been inhibited in a 
persistent manner.
LY2951742 and ALD403 are fully humanized monoclonal 
antibodies that potently and selectively bind to CGRP.111,123 
ALD403, in particular, binds to both α and β forms of human 
CGRP (affinity K
d
 ,20 pM123), and LBR-101 binds to the 
peptide receptor-binding site of CGRP.113 After antibody-
dependent sequestration of circulating CGRP, the peptide 
receptors might remain available to other endogenous ligands 
supporting ongoing receptor signal transduction in neurons 
and nonneuronal cells.
Advances in antibody design technology have paved the 
way for an improved generation of therapeutic antibodies.124 
Thus, therapeutic antibodies can be modified to increase their 
specificity125 and decrease their risk of adverse reactions, for 
example, by modulating their immune effector functions, 
extending their half-life, and optimizing their antigen-binding 
domains. The antibody stability is an important issue since, in 
order to neutralize CGRP, whose plasma levels are fluctuating 
during the course of the illness, high antibody concentra-
tions should be attained. This goal is, however, not without 
problems as mechanism-related and nonspecific adverse 
reactions have been reported, including immunogenicity.126 
Guidelines for the therapeutic use of antibodies have recently 
been published (http://www.ema.europa.eu/ema/). It should 
be noted that certain pharmacological antagonists of CGRP 
can also induce adverse reactions as shown, for example, by 
interruption of the trials with the CGRP receptor antagonist 
telcagepant.127
BNP is a potential endogenous 
negative regulator of nociceptive 
signaling
While CGRP is the prototypical neuropeptide for the sensiti-
zation of TG neurons, it seems likely that there are also endog-
enous neuropeptides to downregulate the activity of P2X3 
receptors and they would, thus, represent an intrinsic negative 
feedback system to control pain sensitivity. Recent evidence 
has been gathered in support of a potential involvement of 
the natriuretic peptide system in the modulation of peripheral 
sensory neuron nociceptive signaling.128–131 The natriuretic 
peptides are a family of structurally related hormones widely 
known for their important effects on the cardiovascular sys-
tem and the regulation of water–electrolyte homeostasis.132 
These include atrial natriuretic peptide (ANP), BNP, and 
the C-type natriuretic peptide (CNP).133 All three peptides 
showed distinct amino acid sequence that hints to their 
separate genetic origin.
Natriuretic peptides exert their physiologic effects 
through binding, with different affinities, to three mem-
brane receptor subtypes: the natriuretic peptide receptors 
A (NPR-A), B (NPR-B), and C (NPR-C), which are also 
known as guanylate cyclase A (GC-A), B (GC-B), and the 
clearance receptor, respectively. NPR-A is activated mainly 
by ANP and BNP.133,134
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Unlike CGRP, the functional consequences of BNP action 
on neurons are less understood. Nevertheless, while BNP and 
its receptor NPR-A are both expressed in the rat dorsal root 
ganglia (DRG), their signaling may attenuate inflammatory 
pain through a mechanism involving the opening of large-
conductance Ca2+-activated K+ (BK
Ca
) channels.129 Microarray 
gene profiling has indicated that chronic pain models enhance 
BNP and its NPR-A in rat DRG. NPR-C is also present in 
DRG, where it colocalizes with TRPV1 channels. Here, 
however, NPR-C activation by CNP displays diametrically 
opposite effects compared to NPR-A, as it enhances thermal 
hyperalgesia in a TRPV1- and PKC-dependent fashion.128 These 
results indicate the coexistence of functional NPRs in DRG that 
exhibit contrasting effects on pain transduction, which raises 
question on how the two functions are inter-related and whether 
the natriuretic peptide modulatory role can also be generalized 
to cranial ganglia and other pain conditions.
In relation to migraine mechanisms, ANP gene expres-
sion has been shown to increase following experimental 
cortical-spreading depression.135 Moreover, a recent clinical 
report documents that the BNP precursor (proBNP) levels are 
raised in the jugular vein blood during a migraine attack,136 
indicating a potential involvement of BNP in migraine 
pathophysiology.
Many migraine mediators have, in common, the ability 
to alter both neuronal and vascular function (eg, CGRP, sub-
stance P, bradykinin). This property is also shared by natriuretic 
peptides that activate cGMP-dependent pathways via GC in 
vascular cells to induce vasodilation137,138 and to stimulate nitric 
oxide synthase and NO production probably via activation of 
the NPR-C receptor.138,139 Due to the vasoactive properties 
of natriuretic peptides, it has been recently postulated that 
these substances can induce headache.140 Future studies are, 
however, needed to determine the vasoactive properties of the 
natriuretic peptides on cerebral vessels and their potential role 
in migraine. Several lines of evidence show that vasodilation of 
cranial (meningeal) and extracranial arteries is not necessary 
to directly provoke migraine pain as reviewed.61
In rodent TG and DRG, the NPR-A receptor has been 
reported to be expressed only by sensory neurons. In 
mouse TG, NPR-A is present at membrane level in almost 
all (.95%) neurons, and application of exogenous BNP 
rapidly evokes a large increase in cGMP level, a canonical 
effector of BNP,133 and phosphorylation of AKT, a kinase 
downstream of NPR-A activation.141 Such a strong and 
widespread activity of NPR-A receptors outlines a major 
role of this system in controlling neuronal excitability. In 
fact, although application of exogenous BNP does not change 
ATP
TRPV P2X3
Ca2+
Ca2+ K+
CGRP
AC CRL
ATP
−
−
+
PKA
Modulation of
gene expression
AKT
P
PKG
GTP cGMP
cAMP
BNP
NPR-ARAMP
Cell
membrane
Figure 1 idealized scheme depicting modulation by CGRP or BNP of P2X3 and TRPv1 receptors of trigeminal sensory neurons.
Notes: extracellular CGRP binds to its receptor complex comprising, in addition to the CGRP-binding site, the accessory proteins RAMP and CRL. Once this receptor is 
activated, it catalyzes the synthesis of cAMP that, in turn, activates PKA to phosphorylate the intracellular domain of the ATP-sensitive P2X3 receptor with subsequent gain 
of function and facilitation of trigeminal pain signaling. In addition, CGRP receptor activity stimulates P2X3 gene expression to promote synthesis and trafficking of these 
receptors. No apparent effect by CGRP on TRPv1 receptors is reported. extracellular BNP binds to its receptor NPR-A, which catalyzes the synthesis of cGMP that, in turn, 
stimulates phosphorylation of AKT, thereby activating this kinase. Even though the multiple intracellular targets for AKT are not fully known, it is proposed to downregulate 
(probably via a complex intracellular cascade) the activity of TRPv1 as well as P2X3 receptors with an ultimately inhibitory role of the receptor activity. K+ channels crucial 
for stabilizing membrane potential and controlling firing of action potentials are also shown. Positive and negative signs indicate activation and inhibition, respectively.
Abbreviations: AC, adenylate cyclase; BNP, brain natriuretic peptide; Ca2+, calcium channels; CGRP, calcitonin gene-related peptide; CRL, calcitonin receptor-like receptor; 
K+, potassium channels; NPR-A, natriuretic peptide receptor A; PKA, protein kinase A; PKG, protein kinase G; RAMP, receptor activity-modifying protein; TRPV, transient 
receptor potential vanilloid.
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P2X3 receptor activity, the same protocol depresses TRPV1-
mediated currents in TG.142 Furthermore, anantin, a selective 
NPR-A antagonist, slowly and greatly enhances P2X3 recep-
tor function, implying that ambient BNP produced a constitu-
tive downregulation of P2X3 receptors, which could not be 
further intensified by exogenous BNP.142 These data indicate 
the role of this endogenous peptide as a negative regulator of 
trigeminal sensory neuron excitability to nociceptive stimuli 
and should prompt future clinical studies to explore the role 
of NPR-A receptors in migraine. Further studies are required 
to clarify how BNP and CGRP may interact in migraine pain: 
an idealized scheme of the potential regulation by CGRP and 
BNP of TG neuronal function is illustrated in Figure 1.
Conclusion
Somatosensory cortical maps show that the trigeminal territory 
is large and very sensitive to nociceptive stimuli. Thus, to pre-
vent unwanted pain generation with associated allodynia and 
hyperalgesia as observed in chronic pain syndromes, potent 
intrinsic regulators should exist to counteract the sensitization 
elicited by neuropeptides like CGRP. While current interest in 
novel treatments for migraine is centered on the goal of block-
ing either CGRP or its receptors, future studies are necessary to 
find out whether boosting intrinsic negative regulators that may 
comprise K+ channels, endocannabinoids, or neuromodulatory 
peptides might be a viable approach to treat migraine.
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